Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Delivering health care in Indonesia is a challenge, made more difficult by the geography and distances. Our EOCRU unit specialises in clinical trials on tropical infections, particularly Plasmodium vivax malaria. Current treatments with primaquine are effective but very toxic for patients with G6PD deficiency. Better point of care diagnostics can help us treat all patients safely.

Q: Which infectious diseases are a big problem in Indonesia?

Kevin Baird: I think it is the same infections that affect tropical countries that struggle with getting healthcare services out to their peripheries, where people have difficulty accessing healthcare. It is the same three infections in most tropical countries: HIV, tuberculosis and malaria - the Global Fund's big three, those are good investments. There are also many other important infections that are not typically addressed in Indonesia: lymphatic filariasis, dengue fever, Japanese encephalitis, leptospirosis and others, that I can't tick off.

It is important to realise that Indonesia is a very large country. It has 250 million people, 14,000 islands and over 5000 kilometres in length. To give you a perspective, that's like from London to Kabul, Afghanistan. It is a massive piece of real estate and the Indonesian government struggles to provide adequate health care services all across that and on every island. They struggle and I think that is one of their key challenges.

Q: How can the burden of those diseases be reduced?

KB: I look at that question through the same lense as the challenges and limitations imposed by geography and economics. Because of my experience in Indonesia I have become a strong advocate for very simple and affordable point of care diagnostics. If we can't diagnose infections, we can't treat them, we can't beat them back. The people most affected by these infections do not have access to laboratories. Therefore, if we make progress in point of care diagnostics we are going to make significant progress against many of these infections.

Q: Can you talk about the treatment and prevention of Plasmodium vivax?

KB: That actually is a poster child of the issue of having access to diagnostics. To understand that I have to explain a bit about the biology of that parasite. Plasmodium vivax malaria is actually two infections. On the one hand it causes an acute attack and disease that must be treated, and we have drugs to treat it. On the other hand, it also has a stage that goes dormant, then awakens in the months to follow and causes more clinical attacks. That stage is called hypnozoite and we need a separate treatment for that stage, a 'hypnozoidocide'. The only drug that we have is called primaquine, and that drug happens to be haemolitically toxic to patients who have an inborn abnormality called G6PD deficiency. Unfortunately, this deficiency is quite common where there is malaria, about 8%. If patients receive treatment against that latent stage of Plasmodium vivax and we don't know their G6PD status, their life is at risk. It is so toxic, it can end in death and has ended in death. There is a terrible therapeutic dilemma that we face with every P. vivax patient. Do we give the treatment and risk harm because of G6PD, or do we withhold treatment and allow the parasite to do its harm? A point of care diagnostic that allows us to sort out who is G6PD normal and who is not, allows us to treat people for Plasmodium vivax where today in truth that rarely happens. It is a serious problem and it is a diagnostic problem.

Q: What are the most important lines of research that have developed in the last 5-10 years in this area?

KB: With respect to Plasmodium vivax, we have made great strides in the past decade or so. The malaria research community has sorted out some very important dogma, discredited dogma now. The first is that for decades we were all taught in school that Plasmodium vivax was relatively harmless, it rarely caused death, it was kind of a mild infection. When we go into hospitals and survey patients with the infection, actually we find the opposite is true. Very often, almost as often as with P. falciparum, they develop severe disease syndromes that are associated with the fatal outcome. We now appreciate that Plasmodium vivax threatens life; this gives us a perspective to take it more seriously and perhaps more aggressively.

The second discovery was the importance of that latent hypnozoite stage in terms of the epidemiology of this infection. It turns out that in endemic areas, more than 80% of the acute attacks that we see in patients come from the liver, not the mosquito, and this is very important in terms of understanding how to control the infection. The third important advance, and this is simply connecting those two dots, has informed us of the necessity of addressing this G6PD diagnostic problem and ensuring that every patient that is diagnosed with Plasmodium vivax is treated against those relapses, safely.

Q: Why is your research so important and why should we fund it?

KB: I think there is a simple way to put that: we just need to look back over the past 65 years. Primaquine has been available for 65 years, but the people most in need of it have had no access to it. All we ned to do is think about those decades, the untreated infections and the clinical attacks that have occurred. These are uncountable numbers of infections. Now that we understand this problem, we can take steps - and we are - to resolve it and get Plasmodium vivax treated every time.

Q: How does your research fit into translational medicine within the department?

KB: Looking at translational research is simply research aimed more directly at better health outcomes. I think a lot of research laboratories typically advance the front of some technology and move it forward, pushing that envelope of technology. They then try to translate that to a better health outcome, looking for an illness that is relevant. In Indonesia, and this has a lot to do with the geography where very often the sick patient is right in front of us, we take the inverse approach. Our starting point for translational research is a sick patient, and then to shop the available technology to see how we can improve this patient's health outcome.

That approach largely explains the emphasis of clinical trials at the unit in Jakarta. We mostly do clinical trials and I view that as a technology: doing randomised controlled trials is not simple, it is a technology and it is a skill set that has to be acquired by practise and learning, and that is what we try to do in Indonesia. We develop a team that can do randomised clinical trials that can be applied not just to malaria but to other infections. In fact, my team will be undertaking a randomised controlled trial for TB meningitis at two hospitals in Jakarta this year. It is the same people and the same skill sets, but it is a different disease and that is the business of translational medicine. I might add that our Indonesian friends and partners embrace this very much. This is what they want and expect from us: better health outcomes for their patients, and that is what we strive to deliver.

Kevin Baird


Professor Kevin Baird leads our Eijkman-Oxford Clinical Research Unit (EOCRU) in Jakarta, Indonesia. The unit develops clinical trial models for clinical interventions for preventing and treating malaria. EOCRU also conducts basic laboratory bench, clinical, and field research on G6PD deficiency, a genetic disorder that impacts the prevention and treatment of Plasmodium vivax malaria.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.